Xeris Biopharma Insider: CEO Kevin McCulloch Sells 15,000 Shares on Rule 10b5‑1 Plan Amid Strong Revenue Outlook
Kevin McCulloch’s 15,000‑share sale at Xeris Biopharma is a routine 10b‑5 plan liquidity move, not a signal of weakness amid strong revenue outlook and 14.27% monthly gains.
- Xeris Biopharma Holdings Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read